Tavexia Lifecare Acquires 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore
Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 13 Oct 2026, 12:14 am
Tavexia Lifecare Acquires 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore On 12th Oct'26, Tavexia Lifecare approved acquiring a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 Crore via cash subscription of 2,09,97,180 fresh equity shares at ₹32 per share. The acquisition provides immediate manufacturing capacity at MIDC Tarapur, Maharashtra. Alongside altering its Memorandum of Association, Tavexia is expanding into APIs, finished dosage formulations, CDMO/CRAMS, and nutraceuticals to capitalize on "China+1" tailwinds. The company plans to fund this roadmap through equity or convertible instruments.
Original exchange filing (PDF)
More announcements from Sattva Sukun Lifecare Ltd
- Financial Result · 05 Nov 2026
- Announcement · 05 Nov 2026
- Board has Approved in Change in RTA · 05 Nov 2026
- Result · 05 Nov 2026
- Outcome of Board Meeting · 05 Nov 2026
- Tavexia Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting · 04 Nov 2026
- Disclosure under regulation 30 · 12 Oct 2026
- Disclosure under regulation 30 · 08 Oct 2026
